Synergistic Combination of Irinotecan and Rapamycin Orally Delivered by Nanoemulsion for Enhancing Therapeutic Efficacy of Pancreatic Cancer

Yu Hsuan Liu, Ling Chun Chen, Wen Ting Cheng, Pu Sheng Wei, Chien Ming Hsieh, Ming Thau Sheu, Shyr Yi Lin, Hsiu O. Ho, Hong Liang Lin

研究成果: 雜誌貢獻文章同行評審

1 引文 斯高帕斯(Scopus)

摘要

In recent years, combining different types of therapy has emerged as an advanced strategy for cancer treatment. In these combination therapies, oral delivery of anticancer drugs is more convenient and compliant. This study developed an irinotecan/rapamycin-loaded oral lecithin-based self-nanoemulsifying nanoemulsion preconcentrate (LBSNENPir/ra) and evaluated its synergistic combination effects on pancreatic cancer. LBSNENP loaded with irinotecan and rapamycin at a ratio of 1:1 (LBSNENPir10/ra10) had a better drug release profile and smaller particle size (
原文英語
文章編號473
期刊Pharmaceutics
15
發行號2
DOIs
出版狀態已發佈 - 2月 2023

ASJC Scopus subject areas

  • 藥學科學

指紋

深入研究「Synergistic Combination of Irinotecan and Rapamycin Orally Delivered by Nanoemulsion for Enhancing Therapeutic Efficacy of Pancreatic Cancer」主題。共同形成了獨特的指紋。

引用此